

Cover Story
NCI
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays - Natalie Phelps, whose clinical trial was delayed due to RIFs, dies of colon cancer
- GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
- Shane Jacobson talks about his to-do list for ACS
Boost research, forge closer ties with cancer centers, launch an all-out campaign for resources














